home All News open_in_new Full Article

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced the successful completion of its inaugural Rated Public Bond of €500 million with a coupon of 3.875%, maturing in March 2032. Following the disclosure of the […]



Ipsen issued a €500 million inaugural rated public bond with a 3.875% coupon, maturing in March 2032. The issuance is part of Ipsen’s refinancing plan, which included a €1.5 billion revolving credit facility renewal. The bond supports Ipsen's growth strategy. Ipsen is a global biopharmaceutical company focused on Oncology, Rare Disease, and Neuroscience. Contact information for investors and media is provided. Forward-looking statements are based on Ipsen's management strategy, views, and assumptions.

today 5 h. ago attach_file Economics

attach_file Other
attach_file Economics
attach_file Politics
attach_file Society
attach_file Politics
attach_file Other
attach_file Politics
attach_file Other
attach_file Economics
attach_file Other
attach_file Society
attach_file Other
attach_file Culture
attach_file Other
attach_file Other
attach_file Politics
attach_file Other
attach_file Society
attach_file Other
attach_file Economics


ID: 4065242618
Add Watch Country

arrow_drop_down